Experimental mRNA inhalation therapy targets rare lung disease

NCT ID NCT06600425

Completed Disease control Sponsor: ReCode Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests an inhaled mRNA therapy called RCT1100 in 7 adults with primary ciliary dyskinesia caused by DNAI1 gene mutations. The goal is to see if the treatment is safe and can help restore ciliary function in the lungs. It is a small, open-label trial focused on safety and preliminary effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RCT1100 mRNA therapy
What this could lead to: If successful, this could point toward a treatment that improves ciliary function and respiratory symptoms in people with primary ciliary dyskinesia.
What could go wrong: This is a very early, small Phase 1b study with only 7 participants, so results may not apply broadly. The therapy is still experimental and safety is the main focus.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CILIARY DYSKINESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary ciliary dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CILIARY DYSKINESIA

Contacts and locations

Locations

Royal Brompton Hospital

London, SW3 6NP, United Kingdom
University Hospital Southampton NHS Foundation Trust

Southampton, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.